P.A.W. Capital’s Regenxbio RGNX Stock Holding History

P.A.W. Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-40,000	Closed	-$1.81M	–	67
2020 Q4	$1.81M	Sell	40,000 -35,000	-47%	-$1.22M	1.6%	18
2020 Q3	$2.06M	Buy	75,000 +5,000	+7%	+$163K	2.25%	18
2020 Q2	$2.58M	Buy	70,000 +20,000	+40%	+$746K	2.92%	15
2020 Q1	$1.62M	Buy	50,000 +15,000	+43%	+$625K	2.18%	19
2019 Q4	$1.43M	Sell	35,000 -30,000	-46%	-$1.19M	1.53%	23
2019 Q3	$2.31M	Buy	65,000 +35,000	+117%	+$1.42M	2.89%	10
2019 Q2	$1.54M	Hold	30,000	–	–	1.67%	23
2019 Q1	$1.72M	Buy	+30,000	New	+$1.49M	1.7%	21

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

P.A.W. Capital's RGNX Position: Q1 2021 in Review

P.A.W. Capital sold out of Regenxbio (RGNX) in Q1 2021, closing a stake of 40,000 shares — an estimated $1.81M sold.

P.A.W. Capital first reported a position in RGNX in Q1 2019 and held it in 8 quarters. The position peaked at $2.58M in Q2 2020. 184 funds tracked by Wall St. Rank hold RGNX as of Q1 2021.

P.A.W. Capital reported no remaining Regenxbio position as of Q1 2021 after selling out during the quarter.
P.A.W. Capital sold 40,000 Regenxbio shares in Q1 2021, an estimated $1.81M.
P.A.W. Capital first reported a position in Regenxbio in Q1 2019 and held it in 8 quarters.
P.A.W. Capital's Regenxbio position peaked at $2.58M in Q2 2020.
184 funds tracked by Wall St. Rank held Regenxbio as of Q1 2021.

Based on P.A.W. Capital's 13F filing for Q1 2021, filed 10 May 2021.